Actively Recruiting
Psychiatric Disorders in Addiction - Interest of Screening and Influence on Relapse
Led by University Hospital, Strasbourg, France · Updated on 2025-06-22
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying how psychiatric diagnoses affect the risk of relapse in patients hospitalized in complex detoxification units for addiction. The goal is to better understand which psychiatric conditions increase relapse risk and to improve patient care to reduce this risk. The study also evaluates how screening questionnaires can help make psychiatric diagnoses more reliable. This is an observational study involving patients aged 16 and older who were hospitalized in a specialized withdrawal unit within a defined time frame. During the study, researchers will analyze various psychiatric and addiction-related scores, including insomnia severity, depression, anxiety, PTSD, addiction severity, ADHD, autism traits, and emotion dysregulation, all measured at 22 months. Participants will not receive experimental treatments but will be observed and assessed through questionnaires and clinical evaluations over time. The study will track these psychological and addiction-related scores to understand their relationship with relapse. The research is sponsored by the University Hospital in Strasbourg, France, and participants' involvement includes completing assessments during the study period until the study ends in October 2026.
CONDITIONS
Brief Title
Psychiatric Disorders in Addiction - Interest of Screening and Influence on Relapse
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subject aged 65 16 years
- Hospitalized in the complex withdrawal unit of the Strasbourg psychiatric clinic between January 1, 2024, and November 1, 2024
You will not qualify if you...
- Refusal to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 22 months
Participants are observed over time to assess psychiatric disorder symptoms and addiction relapse.
Assessments at baseline and at 22 months
Trial Site Locations
Total: 1 location
1
Service d'Addictologie - CHU de Strasbourg - France
Strasbourg, France, 67091
Actively Recruiting
Research Team
A
Amaury DURPOIX, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here